卵巢癌患者血清肿瘤干细胞标志物CD133和miR-145的临床价值  

Clinical significance of serum tumor stem cell marker CD133 and miR-145 in patients with ovarian cancer

作　　者：王丹[1,2] 王莉 王治洁[2] 

机构地区：[1]同济大学医学院,上海200092 [2]上海市第八人民医院妇产科,上海200235 [3]抚顺市中心医院妇科,辽宁抚顺116300

出　　处：《中国妇幼健康研究》2016年第4期460-462,共3页Chinese Journal of Woman and Child Health Research

基　　金：上海市徐汇区卫生局医学科研课题青年资助项目(编号:SHXH201207)

摘　　要：目的观察卵巢癌患者血清CD133和miR-145的表达及其对预后的影响。方法选择2010年1月至2014年6月在同济大学医学院、上海市第八人民医院和抚顺中心医院手术的卵巢癌患者84例为卵巢癌组;良性肿瘤手术的患者30例为对照组。用qRT-PCP的方法测定血清CD133和miR-145相对表达量,分析CD133和miR-145表达量与年龄、肿瘤直径、病理类型、分化程度、CA125水平和是否转移分期的关系。结果卵巢癌患者的血清CD133相对表达明显高于对照组(t=5.34,P<0.01),治疗后明显降低(t=8.25,P<0.01);而miR-145相对表达量明显低于对照组(t=5.06,P<0.01),治疗后明显升高(t=10.96,P<0.01)。卵巢癌患者血清CD133和miR-145表达量与年龄、肿瘤直径和病理类型无明显的相关性(t/F值为0.03~0.93,均P>0.05),血清CD133和miR-145表达量与肿瘤分化程度、CA125水平、淋巴转移和FIGO分期呈明显的相关性(t/F值为2.01~28.96,均P<0.05)。术后随访发现CD133高表达组的1年复发率为76.79%,明显高于低表达组的42.86%(x^2=8.06,P<0.05)。miR-145高表达组的1年复发率为43.59%,明显低于低表达组的84.44%(x^2=13.67,P<0.05)。结论 CD133在卵巢癌患者的血清呈高表达,而miR-145呈低表达,两者参与了卵巢癌的发生发展过程,两者联合检测对于诊断和评估预后具有重要的临床价值。Objective To observe the expressions of serum CD133 and miR-145 in patients with ovarian cancer and their impact on prognosis. Methods From January 2010 to June 2014 totally 84 cases of ovarian cancer undergoing surgery in Medical College of Tongji University, Shanghai Eighth People＇ s Hospital or Fushun Central Hospital were selected in ovarian cancer group. Thirty cases of benign tumor were selected in control group. The serum expressions of CD133 and miR-145 were detected by qRT-PCP method, and the relationship between them and age, tumor size, histological type, degree of differentiation, CA125 level as well as metastasis were analyzed. Results The serum CD133 expression level in ovarian cancer group was significantly higher than that in the control group （t = 5.34, P 〈 0.01 ） and significantly lowered after surgery compared with that before surgery （ t = 8.25, P 〈 0.01 ）. The expression level of miR-145 was significantly lower than that in the control group （ t = 5.06, P 〈 0.01 ） and significantly increased after surgery than that before surgery （t = 10. 96, P 〈 0.01 ）. CD133 and miR-145 expressions in ovarian cancer patients were not significantly correlated with age, tumor size and histological type （ t/F value ranged 0. 03 - 0. 93, all P 〉 0. 05 ）, but they were obviously correlated with tumor differentiation, CA125 level, lymph node metastasis and FIGO stage （t/F value ranged 2.01 -28.96, all P 〈 0.05 ）. Postoperative follow-up revealed that the 1-year recurrence rate was 76.79% in patients with high expression of CD133, which was significantly higher than 42.86% in patients with low expression （X2 = 8.06 ,P 〈 0.05 ）. In patients with high expression of miR-145 1-year recurrence rate was 43.59%, which was significantly lower than 84.44% in those with low expression （X： = 13.63, P 〈 0.05 ）. Conclusion The serum expression of CD133 is high but miR-145 is low in patients with ovarian cancer. They both involve in the development and progTession of ovarian c

关 键 词：卵巢癌 CD133 MIR-145 诊断 预后 

分 类 号：R711.7[医药卫生—妇产科学]